No annual revenue total was found in MINERALYS THERAPEUTICS, INC.'s SEC filings.
Mineralys Therapeutics, Inc. (MLYS) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$142.4 million. As of Sep 30, 2026 it held $101.3 million in cash and investments and $100,000 in total debt.
Revenue
—
Net income (TTM)
$-369.97M
-115.9% vs year-ago TTM
Operating cash flow (TTM)
$-153.01M
+10.7% vs year-ago TTM
Free cash flow
$-142.43M
+14.4% vs prior year
EPS (TTM)
$-4.38
-53.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
82.40M
+65.3% vs prior year
Net cash
$101.17M
as of Sep 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MLYS (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Radnor, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1933414
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
|---|---|---|---|
| Operating income | -$170.6M | -$192.4M | -$84.7M |
| Net income | -$154.7M | -$177.8M | -$71.9M |
| Diluted EPS | -$2.29 | -$3.66 | -$1.99 |
| Operating cash flow | -$142.4M | -$166.3M | -$81.2M |
| Free cash flow | -$142.4M | -$166.4M | — |
| Total assets | $661.8M | $205.9M | $251.6M |
| Stockholders' equity | $646.7M | $191.3M | $241.2M |
| Cash and investments | $172.9M | $114.1M | $49.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Nov 4, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended
|
Oct 29, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 19, 2026 | Oct 16, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Aug 11, 2026 | Aug 5, 2026 |
All 408 Mineralys Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.